Oculus Innovative Sciences' (OCLS) New Post-Dermal-Procedures Product Receives FDA 510(k) Clearance
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company’s new post-dermal-procedures product.
Under the supervision of a healthcare professional, the product is intended for the removal of foreign material including microogranisms and debris from postdermal procedures.
“Within my practice I utilize the Microcyn Technology (hypochlorous acid or HOCl) post-procedure and have been most impressed with its ability to accelerate the healing process, manage post-procedure symptoms and protect against secondary infections. I find these HOCl products to be safer, non-cytotoxic and a more effective alternative to povidone-iodine and chlorhexidine. Now, with this approval from the FDA, I believe my peers will benefit from adding Microcyn-based products to their treatment protocols,” said Dr. Michael Gold, board-certified dermatologist and cosmetic surgeon, and founder of Gold Skin Care Center, Advanced Aesthetics Medical Spa, the Laser & Rejuvenation Center and Tennessee Clinical Research Center, all located in Nashville, Tennessee.
Oculus’ dermatology division, IntraDerm, will begin marketing the postdermal-procedures product in the United States beginning in March 2017.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Voyager Therapeutics (VYGR) Offers Update on Phase 1b Trial of VY-AADC01 for Advanced Parkinson's Disease
- PG&E Submits $250M Proposal in Support of Electric Vehicles in California (PCG)
- Atmos Energy (ATO) Announces Departure of CFO Bret Eckert
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!